BRCA-FA PATHWAY FUNCTIONS BEYOND DNA REPAIR {#S1}
===========================================

Deficiency in the BRCA-Fancomi anemia (FA) pathway has widespread physiological consequences. Germ-line mutations in the hereditary breast cancer genes such as *BRCA1* and *BRCA2* are highly penetrant and predispose 20%--80% of carriers to breast and ovarian cancer ([@R5]). In addition, biallelic inactivation of BRCA genes causes FA, a rare multigenic disease in which loss of any of the 21 distinct complementation groups, FANC-A, FANC-B, FANC-C, ..., FANC-T, confers disease (for reviews, see [@R7]; [@R18]). Patients are characterized by progressive bone marrow failure, developmental defects, and cancer predisposition. FA patient cells are also exquisitely sensitive to agents that induce DNA interstrand cross-links (ICLs). Consequently, research has focused on understanding the function of the BRCA-FA pathway in ICL repair. In particular, given the role of BRCA proteins in fixing double-strand DNA breaks by homologous recombination (HR), this function was thought to extend to the repair of ICL-induced breaks. However, essential functions in preserving replication have emerged that are independent of HR. This role was not readily apparent because BRCA-FA-deficient cells are not universally sensitive to fork slowing or stalling drugs. Recent advances in studying the biology of DNA replication and associated machinery have clarified roles in replication and the replication stress response and provide a new perspective for understanding BRCA-FA disease and the function of BRCA-FA proteins in cell survival.

BRCA-FA PROTEINS PROTECT STALLED REPLICATION FORKS FROM DEGRADATION {#S2}
===================================================================

A key initial finding linking the BRCA-FA proteins to the replication stress response was the observation that BRCA2 protects stalled replication forks from break formation following treatment with hydroxyurea (HU) that decreases the generation of deoxyribonucelotides through inhibition of ribonucleotide reductase ([@R51]). More recently, BRCA1, BRCA2, FANCD2, and FANCA were shown to protect nascent DNA strands of replication forks stalled by HU. Mechanistically, BRCA1 and BRCA2 protect nascent DNA at stalled forks from MRE11-mediated degradation by loading RAD51 on ssDNA exposed at stalled forks ([@R77]; [@R96]; [@R17]). Correspondingly, in the absence of BRCA1 or BRCA2 nascent DNA strands of stalled replication forks undergo extensive nucleolytic degradation leading to long stretches of single-stranded DNA (ssDNA) ([@R77], [@R78]; [@R44]). Consistent with this mode of action, a degradation phenotype also underlies a RAD51 mutation in patients with an FA-like phenotype ([@R4]; [@R88]; [@R97]). Thus, RAD51 is a key mediator of BRCA function in HR at DNA breaks and in protecting nascent DNA at stalled forks. In both settings, RAD51 loading on ssDNA could restrict MRE11 resection to initiate recombination-based mechanisms to promote repair at breaks and restart at stalled forks. The mechanistic overlap of HR proteins operating in DNA repair and DNA replication were recently reviewed ([@R43]).

Synchrony in fork processing is established in part by the fact that factors regulating DNA end resection also contribute to fork slowing and subsequent restart mechanisms. Consequently, loss of several BRCA-FA factors causes not only fork degradation phenotypes but also slowing and restart defects following replication stress. In particular, RAD51, FANCD2, FANCM, FAN1, and the FANCD2--FAN1 interaction ensure that replication elongation is slowed in response to HU ([@R55]; [@R53]; [@R99]; [@R46]). BRCA-FA-deficient cells also display defects in slowing replication in response to ICLs that were proposed to underlie the pronounced G~2~/M arrest and sensitivity ([@R74]). Even during unperturbed replication, RAD51 loss leads to the accumulation of ssDNA gaps that are visible by electron microscopy (EM) indicating its role in normal replication ([@R52]; [@R34]). Gaps could result from discontinuous replication if DNA synthesis skips over barriers and reinitiates downstream by employing the primase, PrimPol ([@R33]). Whatever the source of gaps, they could lead to extensive resection that underlies fork degradation phenotypes that characterize loss of BRCA-FA proteins. Gaps could be initiating sites for remodelers that mediate aberrant processing in BRCA-FA cells ([@R43]). Future work will ideally reveal how fork slowing, reversal, protection, and recombination are ultimately coordinated and/or linked with other BRCA-FA pathway functions including replication restart ([@R63]; [@R79]; [@R67]; [@R48]; [@R70]), regulation of new origin firing ([@R85]), and traversing the replisome past replication blocking lesions ([@R35]).

DNA REPAIR AND FORK PROTECTION UNDERLIES *BRCA1/2* GENOME STABILITY AND TUMOR SUPPRESSION FUNCTIONS {#S3}
===================================================================================================

These recently identified roles for BRCA-FA pathway in replication fork stability raise the possibility that maintenance of replication fork stability may contribute to its genome preservation and tumor suppression functions. The idea that replication dysfunction independent of HR drives cancer formation is in part supported by analysis of mammary epithelial cells from *BRCA1* mutation carriers that have not yet developed cancer. These premalignant cells were found to show functional HR and DNA damage checkpoint signaling but defects in the protection of stalled replication forks ([@R61]). Moreover, cells carrying *BRCA2* heterozygous truncating mutations showed extensive replication stress--induced fork degradation ([@R84]). Thus, loss of DNA repair may not be the only crucial factor in the etiology of BRCA cancer. More likely, it could be a combined loss of and/or coordination between DNA repair and DNA replication that undermines the maintenance of genome integrity and tumor suppression.

Until recently, restoration of the HR pathway was the only described mechanism by which *BRCA1/2*-mutant cancers survive genotoxins, such as cisplatin or inhibitors of poly(ADP-ribose) polymerase (PARPi) ([@R25]; [@R72], [@R73]). In *BRCA1-*mutant cells, restoration of HR is achieved by several mechanisms including reversion mutations or loss of the nonhomologous end joining (NHEJ) factor, 53BP1 ([@R13], [@R14]). Conversely, in *BRCA2*-mutant cells, restoration of HR is solely achieved by reversion mutations ([@R25]; [@R72], [@R73]). The finding that approximately half of *BRCA2*-mutant cancers develop chemoresistance in the absence of restored HR suggested that reversion-independent resistance mechanisms awaited identification ([@R59]). To define genetic determinants of cisplatin resistance, we performed a genome-wide short-hairpin RNA (shRNA) screen and found that loss of the chromatin remodeler, CHD4, mediates resistance to cisplatin and PARPi in *BRCA2*-mutated cancer ([@R32]). CHD4 depletion did not restore HR but reduced the levels of chromosomal aberrations in *BRCA2*-mutant cells exposed to cisplatin ([@R32]). The elevated resistance and genomic stability correlated with reduced MRE11 chromatin association and increased fork protection ([@R17]). A series of recent publications concur that rewired fork protection confers chemoresistance independent of HR. This is achievable in *BRCA1/2-*deficient cells by several mechanisms, including loss of the chromatin modifier complex MLL3--4/PTIP/MRE11, the fork remodelers, SMARCAL1, HLTF, or ZRANB3, PARP1, the methyltransferase EZH2, and the negative regulator of RAD51, RADX ([@R17]; [@R21]; [@R23]; [@R44]; [@R83]; [@R87]), as well as through up-regulation of FANCD2 ([@R36]; [@R56]). The clinical significance of this mechanism is confirmed by the poor patient response and survival outcomes observed upon restored fork protection ([@R32]; [@R17]; [@R70]). Thus, these factors may prove useful as potential biomarkers of *BRCA1/2*-deficient tumor response to chemotherapy.

DEFINING DEGRADATION FACTORS AND FORK DYNAMICS IN *BRCA1/2*-DEFICIENT CELLS {#S4}
===========================================================================

A common feature of rewired fork protection is that nuclease activity is tempered by various mechanisms. In particular, in *BRCA1/2*-mutant cells, suppressing MRE11-nucleolytic degradation restores fork protection. This can be done with the MRE11 inhibitor mirin or by reestablishing Rad51 filament formation at stalled forks through expression of a RAD51 mutant lacking ATPase activity or by depletion of the anti-RAD51 factor, RADX ([@R77]; [@R23]). In addition, loss of factors that facilitate the recruitment of MRE11 to stalled forks such as PARP1, PTIP, or CHD4 restores fork protection in *BRCA1/2*-deficient cells ([Table 1](#T1){ref-type="table"}; [@R17]; [@R21]). Given that MRE11 has limited nucleolytic activity ([@R15]), other nucleases likely contribute to fork degradation. In particular, CtIP initiates the MRE11-dependent degradation that is extended by EXO1 ([@R48]). Although it remains debated whether DNA2 contributes to degradation in *BRCA1/2*-deficient cells ([@R17]; [@R80]; [@R44]; [@R48]), DNA2 degrades forks in cells deficient in Abro1, a paralog of the *BRCA1*-interacting protein, Abraxas ([@R92]). An MRE11-independent mechanism has also been described in which the nuclease MUS81 contributes to fork degradation in a pathway with EZH2 ([Table 1](#T1){ref-type="table"}; [@R70]).

Replication fork structures also play a prominent role in nucleolytic degradation. In particular, a reversed replication fork, a so-called "chicken foot," is the target of MRE11 digestion in *BRCA1/2*-deficient cells ([@R57]). Accordingly, fork reversal has been shown to be a prerequisite for fork degradation in *BRCA1/2*-deficient cells ([@R44]). In addition to the remodelers HLTF, SMARCAL1, and ZRANB3 ([@R44]; [@R83]), RAD52, PARP1 and RAD51 drive fork reversal--dependent degradation in *BRCA1/2*-deficient cells ([Table 1](#T1){ref-type="table"}; [@R48]; [@R57]; [@R68]). There are numerous proteins known to generate reversed forks such as DNA helicases FBH1, BLM, WRN, RECQL5 and DNA translocases FANCM and RAD54 ([@R9]; [@R6]; [@R20]; [@R29]; [@R39]; [@R58]). The relevance of these factors to fork degradation in BRCA cancer remains to be investigated. How loss of each remodeler can individually restore fork protection in *BRCA1/2*-deficient cancer also awaits further analysis. Fork remodelers may act in a common pathway; however, HLTF, ZRANB3, and SMARCAL1 do not form a complex ([@R83]). It also remains to be determined how fork remodelers interact with the other pathways of chemoresistance such as EZH2 or MLL3--4/PTIP/MRE11, both of which act independently of each other ([@R70]). Given that the reversed fork structure has exposed DNA ends that mimic DNA double-stranded break ends, it will also be important to determine if in addition to MRE11, these ends are an entry point for NHEJ factors. If so, the reported elevated NHEJ activity that causes genomic instability in BRCA-FA cells ([@R2]; [@R14]; [@R60]) may be suppressed by depletion of fork remodelers. However, as described below, preventing fork reversal and subsequent degradation or NHEJ reactions is not always sufficient for chemoresistance in *BRCA1/2*-deficient tumors.

COMPLEXITY OF REWIRED FORK PROTECTION MECHANISMS {#S5}
================================================

The emerging literature indicates that rewired fork protection mechanisms and their relationship to cell viability, genome stability, and chemoresistance are complex. Rewired fork protection in *BRCA1/2*-deficient cells is achieved by loss of either of three remodelers (HLTF, SMARCAL1, and ZRANB3), PTIP, or PARP1, but loss of CHD4 or EZH2 is restricted to *BRCA2*-mutant cells ([@R32]; [@R21]; [@R69]; [@R70]; [@R83]). These findings suggest that stalled fork structures or compensating pathways in *BRCA1* and *BRCA2* cells may be distinct, but the overall strategy of rewired fork protection remains consistent; forks that escape nucleases are protected from degradation. However, not all routes that escape degradation will confer chemotherapy resistance. RAD51, MRE11, or RAD52 are required for viability of *BRCA1/2*-deficient cells, so their loss will not result in chemoresistance but rather synthetic lethality ([Fig. 1](#F1){ref-type="fig"}; [@R27]; [@R96]; [@R50]). The balance between lethality and survival/chemoresistance also appears dependent on the sequence by which a fork degradation factor is lost, before or after BRCA deficiency. Depletion of PARP1 in *BRCA2*-deficient cells leads to synthetic lethality ([@R26]), whereas deletion of PARP1 before *BRCA2* depletion provides some protective effects ([@R21]).

An additional level of complexity derives from the fact that some proteins possess multiple functions in the replication stress response. For example, RAD51 participates in both the formation and protection of reversed forks ([@R34]; [@R99]). Therefore, depending on which RAD51 function is disrupted, fork protection or degradation could be altered. Further findings show the importance of cellular context, specifically mutational status, for therapy resistance. For example, CHD4 depletion conferred cisplatin resistance in *BRCA2*-mutant cell lines harboring truncated *BRCA2*, but did not improve cisplatin resistance in *BRCA2*-depleted cells, indicating resistance requires the maintenance of a residual *BRCA2*-mutant species (SB Cantor, unpubl.). As different cell types show differing levels of reversed forks ([@R3]), this may explain the findings that SMARCAL1 depletion resulted in chemoresistance in the MCF10A cancer cell line but not in nonmalignant mammary epithelial cells, despite both cell lines being *BRCA1*-deficient ([@R83]). Likewise, *Ptip* depletion in *Brca2*-null mouse B cells improves genome stability and resistance to HU, but in *BRCA2*-null primary human cells fails to restore viability ([@R17]; [@R26]). Ideally future work will unravel these distinctions so that expectations for therapy are better understood.

Finally, it is important to realize that mechanisms of fork protection may vary for different genotoxic agents; mechanisms revealed following treatment of cells with HU may not be informative for mechanism following treatment of cells with cisplatin or PARPi, as these agents have distinct modes of disrupting replication. For example, EZH2 and MUS81 are required for the restart of replication in *BRCA2*-deficient cells following their release from HU ([@R48]; [@R70]). HU treatment promotes replication fork reversal ([@R99]), and reversed forks are extensively resected by nucleases in *BRCA2*-deficient cells. MUS81 cleaves the over-resected reversed DNA forks in *BRCA2*-deficient cells and promotes POLD3-dependent fork rescue, explaining their dependence on MUS81 for replication fork progression and resistance to HU ([@R47]; [@R48]). Conversely, following treatment with PARPi, it is less clear how MUS81 depletion achieves PARPi resistance in *BRCA2*-deficient cells ([@R70]). In particular, MUS81 is probably not required for fork restart upon treatment with PARPi because PARPi suppresses fork slowing and reversal depriving cells of a MUS81 substrate ([@R82]; [@R68]). Likewise, it remains to be determined if similar to depletion of SMARCAL1, ZRANB3 depletion confers cisplatin/PARPi resistance. ZRANB3 depletion restores fork protection in distinct cell systems; however, genomic instability is increased or decreased in *BRCA1/2*-deficient cells depending on the source of replication stress ([@R57]; [@R83]).

REWIRED FORK PROTECTION AND REPLICATION PROGRESSION WITHOUT FORK REVERSAL {#S6}
=========================================================================

When rewired fork protection confers therapy resistance in *BRCA1/2*-mutant cells, the mechanism of replication should be quite different than as found in *BRCA1/2*-proficient cells. In this regard, it is important to note that upon replication stress, replication forks typically slow and reverse ([@R99]). As described above, rewired fork protection achieved through suppression of HLTF, SMARCAL1, ZRANB3, PARP1, and RAD51 is expected to suppress fork reversal. Even though reversed forks are dangerous species that present DNA ends for resection, ssDNA generation, and fork degradation, they also serve to liberate DNA lesions from replisome entanglements, allowing more efficient DNA repair processing. DNA ends in reversed forks also provide DNA substrates for recombination. In addition, the reversed fork is thought to facilitate other strategies for repair or bypass of DNA lesions, such as template switch (TS). TS is an error-free DNA damage tolerance pathway that uses the newly synthesized daughter strand DNA for homology-directed repair to bypass lesions (for review, see [@R54]). Access to recombination, TS, and other repair mechanisms through fork remodeling activities is an important genome stabilizing response to stress that limits fork breakage ([@R68]; [@R58]). Thus, rewired fork protection that limits replication fork slowing and reversal should compromise genomic stability. In BRCA-deficient cancer cells, however, fork reversal could have dire consequences given that its loss provides genomic stability and chemoresistance.

Clues to replication progression mechanisms that confer therapy resistance come from how other activities are altered in *BRCA1/2*-deficient cells that have rewired fork protection. In particular, depletion of HLTF not only results in loss of fork reversal, but TS is also disrupted. This stems from the role of HLTF as an E3 ubiquitin ligase responsible for the addition of ubiquitination chains on PCNA, an essential step in TS ([@R12]; [@R49]). Rewired fork protection established through ZRANB3 depletion will also alter the replication stress response. Polyubiquitinated PCNA recruits ZRANB3 to sites of replication stress, both of which are critical for fork reversal ([@R20]; [@R87]) and proposed to mediate TS. In addition to catalyzing the regression of stalled replication forks, ZRANB3 also prevents inappropriate recombination ([@R20]). Therefore, loss of ZRANB3 could elevate aberrant recombination as well as interfere with a polyUb-PCNA-dependent axis required for engagement of TS. Furthermore, loss of ZRANB3-PCNA interaction may allow access of de-ubiquitination enzymes thereby decreasing polyUb-PCNA and in turn increase monoUb-PCNA. If so, loss of ZRANB3, similar to loss of HLTF, could enhance the overall monoUb-PCNA. This result could have great significance as monoUb-PCNA serves as a molecular switch for the error-prone mechanism of translesion synthesis (TLS), a DNA tolerance mechanism that allows the timely bypass of DNA lesions using error-prone TLS polymerases ([@R19]).

REWIRED FORK PROTECTION VIA TLS AT THE FORK {#S7}
===========================================

Could TLS operate at the fork to limit gap formation, maintain replication, and promote chemoresistance in *BRCA1/2*-deficient cells ([Fig. 1](#F1){ref-type="fig"})? TLS is best described for filling in gaps postreplication and operates effectively when restricted from S phase ([@R38]). However, TLS may operate at the fork, as the replisome is passing through the site of DNA damage or other barrier to replication ([@R75]). Indeed, TLS polymerases enable replication to continue despite DNA damage or other barriers induced by chemotherapy because they have low-fidelity, which allows the insertion of nucleotides opposite to bulky DNA lesions that block high-fidelity replicative DNA polymerases. Moreover, when nucleotide pools are reduced as in HU-treated cells, TLS could also tolerate insertion of mismatched nucleotide ([@R24]; [@R65]). Consistent with the role of TLS reactions occurring at the elongating fork, replication fork stalling is observed in cells depleted of TLS polymerases ([@R65], [@R66]). TLS activity at the fork may also be restricted to a subset of polymerases. Whereas Rev3L operates in postreplicative gap filling, Rev1 and Polη are required for TLS at stalled forks ([@R66]).

In considering the role of TLS in rewired fork protection, it is important to note that TLS may be compromised in BRCA-FA cells. Indeed, in some respects, loss of the BRCA-FA pathway phenocopies loss of TLS and vice versa. Sensitivity to ICL-inducing agents is a phenotype attributed to loss of either pathway. Moreover, FA-like phenotypes in the hematopoietic stem cells result from loss of Ub-PCNA ([@R64]). Pathway interconnections between BRCA-FA and TLS are established by interactions and the employment of common ubiquitin-modifying enzymes (for reviews, see [@R40]; [@R41]; [@R28]; [@R86]; [@R11]; [@R19]). Notably the pathways are also genetically linked. Biallelic inactivation of Rev7(FANCV), the regulatory subunit of the TLS polymerase Polζ, underlies the genetic defect in the FA-V complementation group l ([@R10]). One could speculate that TLS defects in *BRCA-FA*-deficient cells selects for compensatory mechanisms that activate TLS downstream from the BRCA-FA pathway. This could underlie how BRCA-FA cells overcome proliferation defects due to endogenous lesions such as aldehyde-induced damage and R-loops, and/or how bone marrow failure transforms into leukemia in FA patients ([@R30]). Moreover, a gain in TLS could eliminate mitotic DNA synthesis that compensates for under-replication ([@R8]) especially in *BRCA2*-deficient cells ([@R47]). Indeed, an investigation of the mutational signature in cells deficient in *BRCA1* suggests a compensatory up-regulation of TLS ([@R98]).

Although it may be easier to tip the balance toward TLS in BRCA-FA cancer cells, the rewired replisome may take this a step further. In particular, TLS could suffice to replace replicative polymerases during replication if gaps are very short, which could be possible if nuclease-dependent resection at the fork is blocked or limited. In addition, the simultaneous loss of RAD51 and associated Pol α ([@R44]) could enable other gap-filling pathways to compensate as the replisome stalls. Indeed, monoUb-PCNA and RAD51 have nonredundant functions in gap filling ([@R34]). A switch to TLS through a series of modifications on PCNA ([@R37]) and increased chromatin access to stalled forks may underlie the mechanism by which CHD4 loss confers therapy resistance. Indeed, CHD4 loss in *BRCA2*-mutant cells reduced chromatin bound MRE11 and RAD51, while also elevating focal accumulation of the E3 ubiquitin ligase RAD18 that is necessary for PCNA ubiquitination ([@R32]; [@R17]). Notably, chromatin-bound RAD51 in *BRCA2*-mutant cells is already very low, but CHD4 depletion reduces this further ([@R32]). Thus, by disrupting the residual RAD51 that operates independent of BRCA2 to promote fork reversal ([@R44]) and/or that captures ssDNA for gap-filling reactions postreplication ([@R31]), CHD4 loss could block fork reversal and degradation as well as liberate ssDNA for TLS reactions at the fork. Other routes to elevated TLS through changes in chromatin access or RAD18 complexes have been described ([@R42]; [@R93]). We also found that the FANCJ DNA helicase has the ability to aberrantly promote TLS and suppress HR when its interaction with BRCA1 or its carboxy-terminal acetylation are disrupted ([@R16]; [@R89], [@R91]). Conceivably, when not properly regulated by BRCA1, FANCJ disrupts fork-remodeling pathways and/or improves TLS efficiency by unfolding DNA secondary structures that interfere with replication. Interestingly, the mismatch repair protein MSH2, which binds secondary structures formed at stalled replication forks, blocks TLS pathways in FANCJ-deficient cells ([@R62]).

Further characterization will be required to decipher the contribution of TLS to chemoresistance and rewired fork protection in BRCA cancers. Nevertheless, it is an important therapeutic target ([@R94]) given the growing body of evidence illustrating a causative role for TLS in the development of chemoresistance ([@R22]; [@R90]; [@R81]). Importantly, significant progress has been made in the development of TLS inhibitors ([@R1]; [@R45]; [@R71]; [@R76]). TLS inhibitors may be efficacious as a first-line combination chemotherapy or prevent chemoresistance via restored fork protection when used in combination with cisplatin or PARPi. It will also be important to determine whether alternative strategies to block HR and/or fork protection mechanisms of chemoresistance such as inhibitors of ATR ([@R95]) disrupt permissive replication mediated by TLS or other pathways at the replication fork.

CONCLUSION {#S8}
==========

The BRCA-FA pathway displays indispensable roles in maintaining genome stability, suppressing tumors, and mediating chemoresistance. It does this, not only through integral roles in DNA repair, but growing evidence indicates the BRCA/FA pathway contributes to the maintenance of replication forks during times of replication stress. In the absence of replication fork maintenance, *BRCA1/2*-mutant cancers are capable of "rewiring" the replication fork to allow replication to proceed. We propose that the TLS bypass pathway plays an important part in the mechanism by which replication forks proceed through replication stress. The role of the FA-BRCA pathway in maintaining replication forks and the newly established role for rewired replication forks in chemoresistance provide exciting new possibilities for the development of new chemotherapeutic interventions.
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![Model of the mechanisms and potential consequences of fork protection in *BRCA1/2* -deficient cells. (*A*) In wild-type (WT cells), when replication stress (represented by X) is encountered in the course of cancer therapy, there is a reversal of replication forks, and the protection of nascent DNA in a BRCA1-, BRCA2-, and Rad51-dependent manner, that limits resection by nucleases such as MRE11, CtIP, and EXO1. Following TS or recombination-based restart, the replication fork is restarted, thereby conferring chemo-resistance. In absence of BRCA1/2, (*B*) Rad51 is no longer stabilized on reversed forks, allowing access of nucleases to nascent DNA, resulting in extensive degradation and chemosensitivity. (*C*) Extensive nascent cell degradation can be avoided by either loss of fork degradation factors or gain in stabilization factors that will allow forks to restart via template switch (TS) and confer chemotherapy resistance if viability is not also compromised. (*D*) Loss of fork reversal will limit fork degradation if translesion synthesis (TLS) is active at the fork and gaps generated by repriming reactions are avoided.](nihms956810f1){#F1}
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Simplified overview of factors whose loss restores fork protection and/or chemoresistance in BRCA1/2-deficient cells

  Factor     Function                                                                                        Fork Protection                                                                                                                       Chromosome stability                                                                                                                                                                               Chemoresistance                                                                                  Clinical Relevance                                                                                                                                       Publication(s)
  ---------- ----------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------
  MRE11      Nuclease that degrades nascent DNA in stalled replication forks                                 Inhibition restores fork protection in BRCA2- depleted (V-C8), BRCA1- depleted U2OS and BRCA1- mutant (UWB1) cells.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                [@R77] and [@R78]; [@R96]; [@R48]; [@R57]
  CHD4       Recruits MRE11 to stalled fork                                                                  Depletion restores fork protection in BRCA2- mutant (PEO1) cells.                                                                     Depletion protects against chromosomal aberrations in BRCA2-mutant (PEO1) cells (cisplatin).                                                                                                       Depletion increased resistance in BRCA2-mutant (PEO1, Capanl, FA- D1) cells (cisplatin/PARPi).   Low CHD4 correlated with reduced progression-free survival (PFS) in BRCA2- mutant ovarian cancers                                                        [@R32]; [@R17]
  PARP1      Recruits MRE11 to stalled fork, fork reversal activity                                          Deletion restores fork protection in *Brcat1*^−/−^ or *Brca2*^−/−^B cells and *Brca2*^−/−^ mESC.                                      Deletion protects against chromosomal aberrations in *Brca2*^−/−^ mESC and *Brca1*^−/−^B cells (cisplatin, camptothecin).                                                                                                                                                                           PARP1 deletion reduces tumor- free survival in *Brca2*^−/−^ mouse model.                                                                                 [@R17]; [@R21]
  PTIP       Recruits MRE11 to stalled fork                                                                  Depletion restores fork protection in *Brca1*^−/−^ or *Brca2*^−/−^B cells.                                                            Deletion protects against chromosomal aberrations in *Brca1*^−/−^ or *Brca2*^−/−^B cells (HU, cisplatin, camptothecin).                                                                            Deletion increased resistance in *BRCA1*^−/−^B cells (HU).                                       Low PTIP correlated with reduced PFS in BRCA2-mutant ovarian cancer                                                                                      [@R17]
  HLTF       Fork reversal activity, E3 ubiquitin ligase for PCNA                                            Depletion restores fork protection in BRCA1- or BRCA2- depleted MCF10A cells.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      [@R83]
  SMARCAL1   Fork reversal activity                                                                          Depletion restores fork protection in BRCA1- or BRCA2- depleted MCF10A cells or in BRCA2- depleted *Xenopus* extracts.                Depletion protects against chromosomal aberrations in BRCA1- and BRCA2-depleted MCF10A cells (camptothecin).                                                                                       Depletion increased resistance in BRCA1-mutant (MDA-MB-436) cells (cisplatin/PARPi).             Low SMARCAL1 correlated with reduced overall survival (OS) in BRCA1-mutant breast cancer                                                                 [@R44]; [@R83]
  ZRANB3     Fork reversal activity                                                                          Depletion restores fork protection in BRCA1- or BRCA2- depleted MCF10A cells.                                                         Depletion protects against chromosomal aberrations in BRCA1- and BRCA2-depleted MCF10A cells (camptothecin), Deletion causes increased chromatid breaks/gaps in BRCA2- depleted U2OS cells (HU).                                                                                                                                                                                                                                                             [@R87]; [@R83]; [@R57]
  RAD52      Fork reversal activity, loads Rad51 onto ssDNA, recruits MRE11 to stalled fork                  Depletion restores fork protection in BRCA2- depleted U2OS cells                                                                      Depletion protects against chromosomal breakage in BRCA2-depleted U2OS cells (HU).                                                                                                                                                                                                                                                                                                                                                                           [@R57]
  RAD51      Fork reversal activity, binds and protects ssDNA                                                Depletion restores fork protection in BRCA2- depleted RPE-1 cells                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Mijic et al. 2017
  EXO1       Nuclease that extends MRE11 fork degradation                                                    Depletion restores fork protection in BRCA2- mutant (PEO1) or BRCA1- mutant (UWB1) cells, and BRCA1- or BRCA2- depleted U2OS cells.   Depletion protects against chromosomal aberrations in BRCA2-depleted U2OS (HU).                                                                                                                                                                                                                                                                                                                                                                              [@R48]
  MLL4       Induces histone H3 methylation at Lysine 4 (H3K4) to recruit MRE11 to stalled fork              Deletion restores fork protection in *Brca1*^−/−^ or *Brca2*^−/−^ B cells.                                                            Deletion protects against chromosomal aberrations in *Brca2*^−/−^B cells (PARPi, cisplatin).                                                                                                                                                                                                                                                                                                                                                                 [@R17]
  RADX       Inhibits the accumulation of Rad51 at forks                                                     Depletion restores fork protection in BRCA2- depleted U2OS cells, BRCA2 mutant Capanl cells                                                                                                                                                                                                                                              Depletion increased resistance in BRCA2-depleted U2OS cells (PARPi).                                                                                                                                                                                      [@R23]
  EZH2       Induces trimethylation of histone H3 at Lysine 27 (H3K27me3) to recruit Mus81 to stalled fork   Depletion restores fork protection in BRCA2- mutant (VU423) cells.                                                                    Inhibition protects against chromosomal aberrations in BRCA2-depleted Hela or BRCA2- mutant (VU423) cells (mitomycin C).                                                                           Depletion increases resistance in BRCA2-depleted HeLa cells (PARPi, cisplatin).                  Low EZH2 correlated with reduced PFS in BRCA2-mutant ovarian cancer EZH2 inhibition promotes relapse in *Brca2*^−/−^ breast tumor mouse model (PARPi).   [@R70]
